News

A recent study led by Andrew Sauer, M.D., cardiologist at Saint Luke’s Mid America Heart Institute, showed that for patients with heart failure, hospital participation in the IMPLEMENT-HF initiative improves patient care.

A local man with heart failure who was told numerous times he only had months to live gets a second chance at life after treatment at Saint Luke's.

Ahead of American Heart Month, USA Today talks with Dr. James O’Keefe of the Saint Luke’s Mid America Heart Institute about five steps you can take to reduce your risk of developing heart disease.

A potassium binder helped patients with heart failure who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk.

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

On average, survival benefits of CPR for cardiac arrest could be three times as high for white adults compared to Black adults and twice as high for men compared to women.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.